Сравнительная оценка индукции апоптоза производными платины in vitro
Диссертация
Среди комплексных соединений двухвалентной платины большой интерес представляет отечественный препарат циклоплатам — 8(-)-малатоамин (циклопентиламин) платино (П), который был синтезирован П. А. Чельцовым в лаборатории координационных соединений платиновых металлов Института общей и неорганической химии им. Н. С. Курнакова РАН. Циклоплатам обладает хорошей растворимостью в воде, широким спектром… Читать ещё >
Список литературы
- Багрова С.Г. Результаты IT фазы клинического изучения циклоплатама при резистентных солидных опухолях. // Вопросы онкологии. 2001. Том 47.№ 6. Стр.752−756
- Барышников А.Ю., Шишкин Ю. В. Иммунологические проблемы апоптоза.- Mi: Эдиториал УРСС, 2002.-320с.
- Владимирская Е.Б. Биологические основы противоопухолевой терапии.-М.: Агат-Мед, 2001.-110с.
- Горбачева Л.Б., Васильева С. В. и др. Новый противоопухолевый препарат циклоплатам: цитотоксичность и межнитивые сшивки ДНК.// Антибиотики и химиотерапия, 1999, Том 44 № 4. Стр. 9−12.
- Горбунова В.А., Оборотова Н. А., Чельцов П. А., и др. Новый препарат платины второго поколения циклоплатам, лиофилизированный. // Вестник РОНЦ: — 2001. — № 4. — С. 53−57.
- Горбунова В.А. Препарат* циклоплатам. Результаты клинических испытаний при резистентных солидных опухолях // Вестн. моек, онкол. общества. 2004. — № 11. С. 11−14.
- Семенов Н.Н. Активность оксалиплатина (элоксатина) при платиночувствительных опухолях // Фарматека. 2005. — № 18. — С. 63−65.
- Солнцева Т.И. Влияние циклоплатама на мембранные свойства опухолевых клеток: p-адренергические рецепторы и адгезия на пластике // Циклоплатам: Сб. научи, тр. / М.: ОНЦ РАМН, 1993. -С.100 -106.
- Стручков В.А. Механизм действия циклоплатама на структуры ДНК опухолевых клеток // Циклоплатам: Сб. научн. тр. / М.: ОНЦ РАМН, 1993.-С. 90−99.
- Матвеев Б.П., Бухаркин Б. В., Калинин С. А. Химиотерапия гормонорезистентного рака предстательной железы.//Урология. 2005. № 4. Стр.20−23
- Матвеев Б.П., Горбунова В. А., и др. Циклоплатам в лечении больныхраспространенным раком предстательной желез ы//Ур ология нефрология.1996.№ 3 Стр.34−36.
- Оборотова Н.А. Противоопухолевые субстанции и их лекарственные формы, созданные в РОНЦ им. Н. Н. Блохина РАМН // В сб. Экспериментальная онкология на рубеже веков. Под редакцией Давыдова М. И. и Барышникова А. Ю. М. — 2003. С. 5−58.
- Трещали на Е.М., Жукова О., Герасимова Г. К. Методические указания по изучению противоопухолевой активности фармакологических веществ. // В книге Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.
- Фильченков А. А, Стойка Р. С. Апоптоз и рак, К.: Морион, 1999. -184 с.
- Швембергер И.Н., Гинкул Л. Б. Апоптоз: Роль в нормальном онтогенезе и патологии. 2002. Вопросы онкологии, Том 28. № 2. Стр. 153−171.
- Al-Sarraf М. Treatment of locally advanced head and neck cancer: historical and critical review. // Cancer Control 2002. — Vol.9. — P. 387 399.
- Arando D., Wilson A.J. et al Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. BrJCancer.// 2004-V16-P.260−261.
- Bacso Z., Everson R.B. et al. The DNA of Annexin V-binding apoptotic cells is highly fragmented. //Cancer Reasearch -2000-Vol. 60. P. 46 234 628
- Barry M.A., Behnke C.A. and Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperyheremia // Biochem. Pharmacol. -1990. -Vol.40. -P.2353−2362.
- Basil A., Akkaraju G.R. Regulation of caspase activation and cis-diamminedichloroplatinum (II) induced cell death by protein kinase C. // Biochemistry. -1999. Vol. 38. — P. 4245−4251.
- Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. // EMBO Rep. 2002. Vol. 3. — P. 420−425.
- Beretta G.L., Righetti S.C., Lombardi L. et al. Electron microscopy analysis of early localization of cisplatin* in ovarian carcinoma cells. // UltrastructPathol.-2002. Vol.26.-P. 331−334
- Boulikas T. DNA lesion-recognizing proteins and the p53 connection. -1996. Vol- 16. — P.225−242.
- Boulikas Т., Lundstrom K. Viral and non-viral vectors in gene therapy: technology development and* clinical trials. // Technol Cancer Res Treat. -2003.-P. 471−86.
- Boulikas Т., Vougiouka M. Cisplatin and platinum drugs at the molecular level. // Oncol Rep. 2003. — Vol.16. — P. 1663−1682.
- Bossy-Wetzel E, Green DR. Detection of apoptosis by Annexin V labeling. Methods Enzymol 2000−322:15−18.
- Brabec V., Kasparkova J. Modifications of DNA by platinum complexes relation to resistance of tumors to platinum antitumor drugs.//Drug Resistance Updates -2005-V.8.-P.131−146
- Bniijnincx P.C., Sadler P.J. New trends for metal complexes with anticancer activity.// Current opinion in Chemical Biology -2007 -V.12.-P.l-10
- Caglar К., Kinalp С., Arpaci F et al. Cmniilative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by analogous stem-cell transplantation. // Nephrol Dial. Transplant. 2002: -Vol. 17.-P.1931−1935
- Calabresi P. and Chabner B.A. Chemotherapy of neoplastic diseases // In Pharmacological Basis of Therapeutics, Eight Edition. -1990. -P.1202−1263.
- Capizzi R.L. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. // Semin Oncol. 1999. — Vol. 26. — P. 72−81
- Caraceni A., Martini C., Spatti G. et al. Recovering optic, neuritis during systemic cisplatin and carboplatin, chemotherapy. // Acta Neurol Scandr -1997.-Vol: 96.-P. 260−261
- S.G. Chaney, S.L. Campbell, B. Temple, E. Bassett, Y. Wu and M. Faldu, Protein interactions with platinum-DNA adducts: from structure to function, J InorgBiochem 98 (2004) (10), pp. 1551−1559.
- Chollet P., Bensmaine M.A., Brienza S. Single agent activity of oxaliplatin in heavity pretreated advanced epithelial ovarian cancer // Ann. Oncol. -1996.-Vol. 7.-P. 1065−1070.
- Crown J., Donovan N. et al: Caspase 3 in Brest Cancer.// Clinical Cancer Research -2003-V9.-P.738−742.
- Denkert C., Schmitt W.D., Berger S. et al. Expression of mitogen-activated kinase phosphatase-1 (MKP-l) in primary human ovarian carcinoma. // Int J Cancer. 2002. — Vol. 102. — P. 507−513.
- Douglas J. Taatjes • Burton E. Sobel • Ralph C. Budd Morphological and cytochemical determination of cell death by apoptosis Histochem Cell Biol (2008) 129:33−43
- Earnshaw W.C. Nuclear changes in apoptosis. // Curr.Opin. Cell Biol. -1995.-Vol.7.-P.337−343.
- Eastman A., Schulte N., Sheibani N. et al. Mechanism of resistance to platinum drugs. // In: Nicolini M ed. Platinum and other metal coordination compounds in cancer chemotherapy. Boston. 1988. — P. 178−196.
- Edelman J.M. Past, present and future of gemcitabine and carboplatin regimens in an advanced non-small cell lung cancer. // Lung Cancer. — 2002.-Vol. 38.-P. 37−43.
- Emert-Sedlak L., Shangary S et al. Involvement of cathesin D in chemotherapy-induced cytochrome с release, caspase activation, and cell death. Mol Cancer Ther. 2005 V.5 P.733−742
- Epstein R.G. Drug-induced DNA damage and tumor chemosensitivity // J. Clin. Oncol. -1990. Vol.8. — 2062−2084.
- Fadok V.A., Voelker P.A., Campbell J.J. et al. Exposure of phosphatidylethanol-amine on the surface of apoptotic cells // Exp. Cell. Res.-1992. -Vol.232. -P.430−434.
- Falcieri E, Martelli AM, Bareggi R et al. The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 without concomitant DNA fragmentation. Biochem Biophys Res Com. -1993. -Vol.193. -P.19−23.
- Foster R.S. Early stage testis cancer. // Curr Treat Options Oncol. 2001. -Vol. -2. -P. 413−419.
- Gelasco A., Lippard SJ. NMR solution structure of a DNA dodecamer duplex containing a cis-ammineplatinum (II) d (GpG) intrastand cross-link, the major adduct of the anticancer drug cisplatin. // Biochemistry. 1998. -Vol. 37.-P. 9230−9239.
- Galea A.M., Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. // Biochim Biophys Acta. 2002. — Vol. -1579.-P. 142−152.
- Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G Cell death modalities: classiWcations and pathophysiological implications. Cell Death DiVer.- -2007.- Vol. 14.-P. 1237−124
- Gavrieli Y, Sherman Y, and Ben Sasson S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation // J. Cell Biol. -1992. -Vol.119. -P.493−501.
- Gong J.G., Costanzo A., Yang H.Q. et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. // Nature. -1999. Vol. 399. — P. 708−712.
- Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks individual apoptotic cells by the in situ by the terminal deoxynucleotidyl transferase and nick translation assays // Cancer Res. -1993a. -Vol.52. -P.1945−1951.
- Gown AM, Willingham MC Improved detection of apoptotic cells in archival paraYn sections: immunohistochemistry using antibodies to cleaved caspase 3 // J Histochem Cytochem.- 2002.-Vol 50, — P.449−454.
- Godard Т., Deslandes E., Lebailly P. et al. Early detection of staurosporine-induced apoptosis //Histchem. Cell Biol. -1999. -Vol.112. -P.155−161.
- Hickman J.A. Apoptosis induced by anticancer drugs // Cancer Met. Rev. -1992. -Vol.11.-P.121−139.
- Harries M., Kaye S.B. Recent advances in the treatment of epithelial ovarian cancer. // Expert Opin Investig Drugs. 2001. — Vol. — 110. — P. 1714−1724.
- Hay M.P. ZD-0473 AstraZeneka. // Curr. Opin Investig.Drugs. 2000. -Vol. l.-P. 263−266.
- Henkels K.M., Turchi J.J. Cisplatin-induced apoptosis proceeds de caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer. // Cancer Res. 1999. -Vol. 59. p. 30 773 083.
- Hesketh R. Gene therapy for cancer. In: The oncogene and tumor suppressor gene // Hesketh R ed. Cambridge, UK. 1997. — P. 61−69.
- Hill J.M., Speer R.J. Organo-platinum complexes as antitumor agents. // Anticancer Res. 1982. — Vol. 2. -P.173−186.
- Inuma H., Maruyama K., Okinaga К et al. Intracellular targeting therapy of cisplatin-encapsulated transferring-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. // Int J Cancer. 2002. — Vol. 99.-P. 130−137.
- Ito Y, Shibata M-A, Kusakabe K, Otsuki Y Method of specific detection of apoptosis using formamide-induced DNA denaturation assay// J Histochem Cytochem.- 2006,-Vol 54.- P.683−692.
- Jamieson E.R., Jacobson M.P., Barnes C.M. et al. Structural and kinetic studies of cisplatin-modified DNA icosamer binding to HMGG1 domain B. // 1999. Vol. 274. — P.2346−12 354.
- Jansen B.A., Brower J., Reedijk J. et al. Glutation induces cellular resistance against cationic dinuclear platinum anticancer drugs. // J Inorg Biochem. 2002. — Vol. 89. — P. 197−202.
- Kaufmann S.H. Induction of endonucleolytic DNA cleavage in humanacute myelogenous leukemia cells by etoposide, camtothecin, and other131cytotoxic anticancer drugs: a cautionary note // Cancer Res.- 1989. -Vol.49. -P.5870−5878.
- Kaufmann S.H., Desnoyers S., Ottaviano Y. et al. Specific proteolytic cleavage of Poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis // Cancer Res.- 1993. Vol.53. — P.3976−3985.
- Kigawa J., Sato S., Shimada M. et al. p53 gene status and chemosensitivity in ovarian cancer. // Hum Cell. 2002. — Vol. 14. г P.165−171.
- Koo MS, Kwo YG et al. Signaling and function of caspase and c-jun N-terminal kinase in cisplatin-induced apoptosis // Mol Cells. 2002. -Vol.13. -P.l94−201.
- Koopman G., Reutelingsperger C.P.M., Kuijten. G.A.M., Keehnen R.M.J., Pals S T. & van Ors M.H.J. Annexin V for Flow Cytometric Detection of phosphatidylserine exspression on В cells undergoing apoptosis // Blood. -1994. Vol.84. — P.1415−1420.
- Kosmidis P., Mylonakis N., Nikolades C. et al. Paclitaxe! plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell* lung cancer: a phase in randomized trial. // J Clin Oncol. 2002. — Vol. 20. — P.3565−3567.
- Labat-Moleur F., Guillerment C., Lorimier P. TUNEL apoptic cell detection in tissue sections: critical evaluation and improvement // The
- Journal of Histochemistry & Cytochemistry. -1998. -Vol.46 (3). -P.327−334.
- T. Latif, L. Wood and C. Connell et al., Phase П study of oral bis (aceto)ammine dicWoro (cyclohexamine)platinum (TV) (JM-216, BMS-182 751) given daily x 5 in hormone refractory prostate cancer (HRPC) // Invest New Drugs.- 2005.-Vol. 1.-P. 79−84.
- Lazebnik YA, Kaufinann SH, Desnoyers S. et al. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE //Nature. -1994, Vol.371. -P.346−347.
- Lee E.K., Regenold W.T., Shapiro P. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteocarcoma and neuroblastoma cell lines. // Anticancer Drugs. 2002. — Vol. 13. — P. 859 968.
- Levresse V., Marek L., Blumberg D. et al. Regulation of platinum-compounds cytotoxicity by the c-Jun N-Terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. // Mol Pharmacol. -2002. Vol. 62. — P. 689−697.
- Lin W.L., Li D.G. et al. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol. //2004-V.19-P.2911−2915.
- Lin X., Okuda Т., Holzer A. et al. The copper transporter CTRI regulates cisplatin uptake in Saccharomyces cerevisasiae. // Mol Pharmacol. 2002. -Vol. 62.-P. 1154−1159.
- Ling Y.H., Priebe W. and Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells // Cancer Res.- 1993. Vol.53. — P.1845−1852.
- Liu W., Staecker H., Stupak H et al. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. // Neuroreport. 1998. — Vol. 9.-P. 2609−2614.
- Mandic A. Cisplatin induces endoplasmatic reticulum stress and nucleus-independent apoptotic pathway. // J Biol Chem. 2003, — Vol. 278. — P. 9100−9196.
- Mani S: Graham M.A. Bregman D.B., et al- Oxaliplatin: a review of evoling concepts //Cancer Invest.- 2002 Vol. 20 — P.246−63:
- Mattern J., Stammler G., Koomagi R. et al. Spontaneous apoptosis in ovarian-cancer: an unfavorable prognostic factor: // Int J Oncol: — 1998. — Vol. 12.-P. 351−354.
- Meyerhardt J.A., Fuchs C.S. Chemotherapy options for gastric cancer. // Semin Radiat Oncol. 2002. Vol. 12. -P: 176−186.
- Mizutani Y., We X.X., Yoshida O. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. // Oncol Rep. -1999: Vol: 6: -P. 979−982.
- Mu D, Tursum M., Duckett D R. et al. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and exicision repair systems. // Mol Cell Bioh 1997. — Vol. 1. — P: 760−769-
- Muracami T, bis X, and? Cong J et al: Induction- of apoptosis by 5-Azacytidine: Drug Concentration-dependent Differences in Cell Cycle Specificity // Cancer Res. -1995. Vol.55. P.3093−3098:
- Nagata J., Kijima H., Hatanaka H. et al. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. // Int J Oncol. 2002. — Vol. 21. — P. 10 211 026.
- Najajreh Y., Perez X.M., Nawarro-Ranninger C. et ah. Novel soluble cationic trans-diaminedichloroplatinum (II) complexes that are active against cisplatin resistant ovarian cell lines. // J Med Chem. 2002. — Vol. 45.-P. 5189−5195.
- Negoescu A., Lorimier P., Labat-Moleur F. et al. TUNEL: Improvement and evaluation of the method for in situ apototic cell identification. // BIOCHEMICA. -1997. -No.2.
- Nehme A., Baskaran R., Nabel S. et al. Induction of JNK and c-Abl signaling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. // Br J Cancer. 1999. — Vol. -79. — P. 1104−1110.
- Niedner H., Christen R., Lin X. et al. Identification of genes that mediate sensitivity to cisplatin. // Mol Pharmacol. 2001. — Vol. 60. — P. 11 531 160.
- Orih M. Fertig G. Presentation of an Assay Format for the Specific Assessment of Caspase 3. // BIOCHEMICA.- 2000.- Vol 4.- P- 35−38.
- Pasetto L.M., D’Andrea M.R. et al. The development of platinum compounds and their possible combination. // Critical Reviews in Oncology// Hematology 2006 — Vol.60 — P.59−75.
- P. Perego, L. Gatti and S.C. Righetti et al., Development of resistance to a trinuclear platinum complex in ovarian carcinoma. // Int J Cancer.- 2003.-Vol. 5.- P. 617−624.
- Pestell K.E., Hobbs S.M., Titley J.C. et al. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. // 2000.-Vol. 57.-P. 503−511.
- Prchal J: T., Throckmorton D. W, Caroll A-J. et al. A common progenitor for human myeloid and lymphoid cells // Nature. -1978: -Vol 274. -P.590−5911
- Rabik CIA Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents.//Cancer Treatment Reviews-2007-Vol.33-P. 9−23
- Reed E. Platinum analogs. In: De Vita V.T., Hellman S A. Eds. Cancer principles and practice of oncology. Philadelphia: JB Lippincort. // 1993. -P. 390−400
- Reed E. Platmum-DNA adduct< nucleotide excision repair, and platinum based anti-cancer chemotherapy. // Cancer Treat Rev. 1998: — Vol. 24. -P.331−344.
- Reed E. Cisplatin: // Cancer Chemother Biol Response Modif. 1999. -Vol. 18. -P.145−152.
- Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis.//Nat Rev Mol Cell Biol. -2004. Vol 11/- P.897−907.
- Rose W., Schuring J. Preclinical antitumor and toxicological proffle of carboxyplatin. // Caner Treat Rev. 1985. — Vol. 18.-P. 1−19.
- Sandercock J., Parmar M.K., Torn V. et al. First line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. // Br. J. Cancer. 2002. — Vol: 87. — P. 815−824.
- Schaaf G.J., Maas R.F., de Groene E. M et al. Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. // Free Radic Res. 2002. — Vol. 36. — P. 835−843.
- Scheeff E.D., Briggs J.M., Howell S.B. Molecular modeling of the intrastand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. // Mol Pharmacol. 1999. — Vol. 56. — P. 633−643.
- Screnci D., Er H.M., Hasmbley T.W. et al. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. // Br J cancer. 1997. — Vol. 7. — P. 502−510.
- Sen S. and D’lncalci M. Apoptosis: biochemical events and relevance to cancer chemotherapy // FEBS Lett. -1992. -Vol307. -P.122−127.
- Sessa S., Capri G., Gianni L. et al. Clinical and pharmacological phasel study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatimim complex. // Ann Oncol. 2000. -Vol. 1 l.-P: 977−983.
- Sharp S. Y, O’Neill C.F., Rogers P. et al. Retention of activity by the new generation platinum agents AMD0473 in four human tumor cell lines possessing acquired resistance to oxaliplatin. // Eur J Cancer. 2002. — Vol. 38.-P. 2309−2315.
- Shen D.W., Goldenberg S., Pastan I. et al. Decreased accumulation of 14C. carboplatin in human cisplatin-resistant cells results from reduced' energy-dependent uptake. // J cell Physiol. 2000. — Vol. 183. — P. 108 116.
- Skladanowski A. and Konopa J. Adriamycin and daunomycin induce programmed cell death-(apoptosis) in tuinor cells // Biochem. Pharmacol. -1992. -Vol.46. -P.375−382.
- Steart D.J. Mechanisms of resistance to cisplatin and carboplatin//Critical Reviews in Oncology/Hematology -2007- V.63-P. 12−31
- C.N. Sternberg, P. Whelan and J. Hetherington et al., Phase Ш trial of satraplatin, an oral platinum plus prednisone versus prednisone alone in patients with hormone-refractoiy prostate cancer// Oncology. -2005, — Vol. 1.-P.2−9.
- Storlad В., Pavlakis N. Oxaliplatin for the treatment of cisplatin -resistant cancer: A systematic review. // Cancer Treatment Reviews -2007. Vol.33. — P.347−357
- Susan Elmore. Apoptosis: A Review of Programmed Cell Death. // Toxicol Pathol. 2007. — Vol: 35.- P. 495−516.
- Takemura G., Fujiwara H. Morphological- aspects of apoptosis inheart diseases. // J Cell Mol Med.- 2006. Vol. 10. P.56−75.
- Tanaka M., Kuwahara E., ShimizuT. et al. New drug BMS-182 751. // Biol Pharm Bull. 1999. — Vol. 22. — P.521−526.
- Tokuchi Y., Isobe H., Takekawa H. et al. Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 singlphoton emission computerized tomography. // Br J Cancer. — 1998. -Vol. 77. -P.1363−1368.
- Veal G.J., Griffin M.J., Price E. et al. A phase 1 study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. // Br J cancer. 2001. — Vol.84. — P. 1029−1035.
- Wan-Long Lin, Ding-Guo Li. et al. Clinical and experimental study of oxaliplatin in treated human gastric carcinoma. // World J. Gastroenterol -2004- Vol. 10(19) P.2911−2915.
- Woessman W., Chen X., Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteocarcoma and neuroblastoma cell lines. // Cancer Chemother Pharmacol. 2002. — Vol. 50.-P. 397−404.
- Wyllie A.H., Morris R.G., Smith A.L. and Dunlop D. Chromatin cleavagein apoptosis: association with condensed chromatin morphology and139dependence on macromolecular synthesis // Am. J. Pathology. -1984. -V.142. -P.67−77.
- Yamada H., Uchida N., Maekawa R. et al. Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. // Cancer Lett. 2001. — Vol. — 172. — P.17−25.
- Yunmbam M.K., Li Q.Q., Mimnaugh E.G. et al. Effects of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. // Int J Oncol. 2001. — Vol. 19. — P.741−748.
- Zhang W., Zhang C., et al. Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells.// Cancer Latters 2007- Vol.255.- P.127−134
- Zhang Т., Guan M., Jin H.Y., Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. // Gynecol Oncol.- 2005.- Vol. 97.- P. 501−507.
- Zhen W., Link С J., O’Connor P.M. et al. Increased gene-specific repair of cisplatin interstand crosslinks in cisplatin resistant human ovarian cancer cells. // Mol Cell Biol. 1992. — Vol. 12. — P.3689−3698.
- Zhong X., Li X., Wang G., et al. Mehanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells.// Int S Oncol.- 2004.- Vol. 25. P. 445−51.